The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 10 of 18
Back to Result List

Phosphorylation of the chromatin remodeling factor DPF3a induces cardiac hypertrophy through releasing HEY repressors from DNA

Please always quote using this URN: urn:nbn:de:bvb:20-opus-166391
  • DPF3 (BAF45c) is a member of the BAF chromatin remodeling complex. Two isoforms have been described, namely DPF3a and DPF3b. The latter binds to acetylated and methylated lysine residues of histones. Here, we elaborate on the role of DPF3a and describe a novel pathway of cardiac gene transcription leading to pathological cardiac hypertrophy. Upon hypertrophic stimuli, casein kinase 2 phosphorylates DPF3a at serine 348. This initiates the interaction of DPF3a with the transcriptional repressors HEY, followed by the release of HEY from the DNA.DPF3 (BAF45c) is a member of the BAF chromatin remodeling complex. Two isoforms have been described, namely DPF3a and DPF3b. The latter binds to acetylated and methylated lysine residues of histones. Here, we elaborate on the role of DPF3a and describe a novel pathway of cardiac gene transcription leading to pathological cardiac hypertrophy. Upon hypertrophic stimuli, casein kinase 2 phosphorylates DPF3a at serine 348. This initiates the interaction of DPF3a with the transcriptional repressors HEY, followed by the release of HEY from the DNA. Moreover, BRG1 is bound by DPF3a, and is thus recruited to HEY genomic targets upon interaction of the two components. Consequently, the transcription of downstream targets such as NPPA and GATA4 is initiated and pathological cardiac hypertrophy is established. In human, DPF3a is significantly up-regulated in hypertrophic hearts of patients with hypertrophic cardiomyopathy or aortic stenosis. Taken together, we show that activation of DPF3a upon hypertrophic stimuli switches cardiac fetal gene expression from being silenced by HEY to being activated by BRG1. Thus, we present a novel pathway for pathological cardiac hypertrophy, whose inhibition is a long-term therapeutic goal for the treatment of the course of heart failure.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Huanhuan Cui, Jenny Schlesinger, Sophia Schoenhals, Martje Tonjes, Ilona Dunkel, David Meierhofer, Elena Cano, Kerstin Schulz, Michael F. Berger, Timm Haack, Salim Abdelilah-Seyfried, Martha L. Bulyk, Sascha Sauer, Silke R. Sperling
URN:urn:nbn:de:bvb:20-opus-166391
Document Type:Journal article
Faculties:Medizinische Fakultät
Language:English
Parent Title (English):Nucleic Acids Research
Year of Completion:2016
Volume:44
Issue:6
Pagenumber:2538-2553
Source:Nucleic Acids Research, 2016, Vol. 44, No. 6, 2538-2553. DOI: 10.1093/nar/gkv1244
DOI:https://doi.org/10.1093/nar/gkv1244
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:DNA; DPF3a; HEY repressors; cardiac hypertrophy; phosphorylation
Release Date:2019/07/05
EU-Project number / Contract (GA) number:289600
OpenAIRE:OpenAIRE
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International